Bulletin
Investor Alert

Market Pulse Archives

Oct. 1, 2020, 8:36 a.m. EDT

Pulmonx prices IPO at $19 a share, above proposed price range

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

By Ciara Linnane

Pulmonx, a maker of treatments for lung diseases including emphysema, priced its initial public offering at $19 a share, above its proposed price range of $17 to $18. The company upsized the deal on Wednesday and raised the proposed price range. The company sold 10 million shares to raise $190 million. Shares will start trading on Nasdaq later Thursday, under the ticker "LUNG." BofA, and Morgan Stanley were lead underwriters on the deal, with Stifel, Wells Fargo and Canaccord acting as co-managers. Proceeds of the deal will be used to hire sales and marketing people, fund R&D, to pay a success fee to Oxford of $1.9 million and for working capital. "We are a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD)," the company says in its prospectus.

Get news alerts on Pulmonx Corp. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.